ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Any hope?

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Dec 06, 2023 2:30pm

106 Views

Post# 35771529

RE:RE:Any hope?

"I remain hopeful about the technical (scientific) outlook for PMN310. Based on pre-clinical data, it looks like it should be an effective and more selective product than anything out there currently, including ACU193 from Acumen ($ABOS)."

But what data do we have thus far that selectivity would make any difference?

G1945V

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs